Atea Pharmaceuticals Stock Analysis

AVIR -  USA Stock  

USD 23.39  0.54  2.36%

The latest indifference towards the small price fluctuations of Atea Pharmaceuticals could raise concerns from retail investors as the firm it trading at a share price of 23.39 on 3,202,900 in volume. The company directors and management did not add any value to Atea Pharmaceuticals investors in May. However, most investors can still diversify their portfolios with Atea Pharmaceuticals to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.98. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Atea Pharmaceuticals partners.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Atea Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Atea Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Atea Pharmaceuticals stock analysis module also helps to analyze the Atea Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Atea Pharmaceuticals Stock Analysis Notes

About 18.0% of the company shares are held by company insiders. The book value of Atea Pharmaceuticals was presently reported as 13.09. The company recorded a loss per share of 0.64. Atea Pharmaceuticals next dividend is scheduled to be issued on the 9th of November 2012. The entity had 1:6 split on the 9th of November 2012. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. For more info on Atea Pharmaceuticals please contact Joseph Patti at 678 221-3343 or go to www.aviragentherapeutics.com.

Atea Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Atea Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Atea Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Atea Pharmaceuticals has very high historical volatility over the last 90 days
Atea Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 48.63 M. Net Loss for the year was (10.95 M) with profit before overhead, payroll, taxes, and interest of 33.65 M.
Atea Pharmaceuticals has a poor financial position based on the latest SEC disclosures
About 58.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.benzinga.com: Atea Pharmaceuticals Shares Spike Higher After The New York Times Reports U.S. Considering Back Cos COVID Drugs - Benzinga

Atea Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Atea Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atea Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report12th of August 2021
Next Earnings Report9th of December 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Atea Pharmaceuticals Largest EPS Surprises

Earnings surprises can significantly impact Atea Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-13
2021-03-31-0.05420.340.3942727 
2021-03-30
2020-12-310.2472.622.373960 
View All Earnings Estimates

Atea Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Atea Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Atea Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Atea Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
20th of May 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
13th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
19th of April 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
7th of April 2021
Unclassified Corporate Event
View
10th of March 2021
Unclassified Corporate Event
View
16th of February 2021
Unclassified Corporate Event
View
10th of February 2021
Unclassified Corporate Event
View
8th of February 2021
Unclassified Corporate Event
View

Atea Pharmaceuticals Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Atea Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atea Pharmaceuticals backward and forwards among themselves. Atea Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Atea Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares10.8 M664.4 M
Cormorant Asset Management LpCommon Shares6.4 M395.9 M
Bain Capital Life Sciences Investors LlcCommon Shares5.6 M346.8 M
Ra Capital Management LpCommon Shares5.4 M331.5 M
Perceptive Advisors LlcCommon Shares3.1 M184.7 M
Price T Rowe Associates IncCommon Shares2.6 M153.8 M
Aju Ib Investment Co LtdCommon SharesM126.5 M
Note, although Atea Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Atea Pharmaceuticals Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.94 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Atea Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Atea Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Atea Pharmaceuticals Profitablity

Atea Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Atea Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Atea Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Atea Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Atea Pharmaceuticals' profitability requires more research than a typical breakdown of Atea Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (22.51) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 24.7 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.25.
Last ReportedProjected for 2021
Return on Investment(18.80) (20.28) 
Return on Average Assets(0.025) (0.0269) 
Return on Average Equity(0.044) (0.0452) 
Return on Invested Capital 0.07  0.07 
Return on Sales(0.20) (0.22) 

Management Efficiency

The entity has return on total asset (ROA) of 1.7 % which means that it generated profit of $1.7 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (3.86) %, meaning that it created substantial loss on money invested by shareholders. Atea Pharmaceuticals management efficiency ratios could be used to measure how well atea pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/19/2021, Return on Invested Capital is likely to grow to 0.07, while Return on Investment is likely to drop (20.28) . Atea Pharmaceuticals Total Assets are relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Total Assets of 863.63 Million. As of 06/19/2021, Current Assets is likely to grow to about 931.6 M, while Net Current Assets as percentage of Total Assets are likely to drop 102.91.
Last ReportedProjected for 2021
Book Value per Share 25.37  27.37 
Enterprise Value over EBIT(275.40) (297.14) 
Enterprise Value over EBITDA(275.60) (297.36) 
Price to Book Value 5.67  5.64 
Tangible Assets Book Value per Share 40.00  43.16 
Enterprise ValueBB
Tangible Asset Value863.6 M931.8 M

Technical Drivers

As of the 19th of June, Atea Pharmaceuticals shows the mean deviation of 4.25, and Risk Adjusted Performance of 0.0209. Atea Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Atea Pharmaceuticals, which can be compared to its rivals. Please confirm Atea Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Atea Pharmaceuticals is priced correctly, providing market reflects its regular price of 23.39 per share. Given that Atea Pharmaceuticals has jensen alpha of 0.0576, we suggest you to validate Atea Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Atea Pharmaceuticals Price Movement Analysis

The output start index for this execution was twenty-eight with a total number of output elements of one hundred thirty-two. The Mid-point over period is an average of Atea Pharmaceuticals highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Atea Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atea Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Atea Pharmaceuticals Predictive Daily Indicators

Atea Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atea Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Atea Pharmaceuticals Forecast Models

Atea Pharmaceuticals time-series forecasting models is one of many Atea Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atea Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Atea Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Atea Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Atea Pharmaceuticals shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Atea Pharmaceuticals. By using and applying Atea Pharmaceuticals Stock analysis, traders can create a robust methodology for identifying Atea Pharmaceuticals entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(75.66) (81.63) 
EBITDA Margin(0.20) (0.22) 
Gross Margin 0.90  0.89 
Profit Margin(0.20) (0.22) 
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase IIIa clinical trial for the treatment of chronic hepatitis C and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Current Atea Pharmaceuticals Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Atea Pharmaceuticals analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Atea Pharmaceuticals analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
33.0Buy2Odds
Atea Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Atea Pharmaceuticals analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Atea Pharmaceuticals stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Atea Pharmaceuticals, talking to its executives and customers, or listening to Atea Pharmaceuticals conference calls.
Atea Pharmaceuticals Analyst Advice Details

Atea Pharmaceuticals Stock Analysis Indicators

Atea Pharmaceuticals stock analysis indicators help investors evaluate how Atea Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Atea Pharmaceuticals shares will generate the highest return on investment. By understating and applying Atea Pharmaceuticals stock analysis, traders can identify Atea Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio2.71
Fifty Two Week Low18.72
Shares Short Prior Month2.24M
Average Daily Volume Last 10 Day1.25M
Average Daily Volume In Three Month885.62k
Shares Percent Shares Out5.14%
Gross Margins69.20%
Short Percent Of Float5.66%
Forward Price Earnings1.94
Float Shares49.08M
Fifty Two Week High94.17
Enterprise Value To Ebitda87.36
Fifty Day Average22.13
Two Hundred Day Average47.69
Enterprise Value To Revenue21.61
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.